Plain-English translation of NCT05803018 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a new injectable medication called for patients with advanced cancers, particularly gynecological cancers that have returned or spread to other parts of the body. The study is looking at whether the medication is safe, how well it works, and how the body processes it. Researchers will also check whether the medication triggers an immune response in the body.
Many patients with advanced gynecological cancers run out of standard treatment options or don't tolerate existing therapies well. This trial explores whether this new medication could offer another treatment choice for people in that situation.
You likely qualify if…
You likely don't qualify if…
You would receive the medication as an intravenous infusion (through a vein) during a 3-week cycle. If the treatment appears to be helping and you are tolerating it well, you can continue receiving additional cycles. Throughout the study, doctors will closely monitor you for side effects, check how your tumor is responding, and run blood tests to measure how your body is processing the medication. The study will continue until your cancer progresses, you experience intolerable side effects, or other reasons make it necessary to stop.
AI-generated summary from trial data · Jun 16, 2026 · Not medical advice
China
Phase
Safety & dosing / Early efficacy
Sponsor
Sichuan Baili Pharmaceutical Co., Ltd.
Collaborators
Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.
Enrollment target
~38 participants
Started
June 2023
Primary completion
December 2026
Age range
18 Years – 75 Years
Last updated on clinicaltrials.gov in September 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Sa Xiao, PHD
Fudan University
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.